Vall d’Hebron Institute of Oncology (VHIO)

Leading translational research to accelerate & advance personalized and targeted therapies against cancer. @iCERCA centre

[Vall d’Hebron Institute of Oncology (VHIO) @VHIO]

More from #ESMO2026!

VHIO researchers are sharing their expertise in scientific and educational sessions, contributing to discussions across different areas of oncology.

Great to see @alerezqallah, @judithbalmana and @crisuarez08 taking part!

[Vall d’Hebron Institute of Oncology (VHIO) @VHIO]

VHIO at #ESMO2026!

Our researchers are sharing their latest work and expertise with the international oncology community in Madrid.

Great to see @MOliveira_MD, @rdienstmann, @EnriquetaFelip and Francesc Salvà contributing to this year's congress!

[Joaquin Mateo @quimmateo]

Our own @fenorlolin from @VHIO is now presenting in Hall 4 at #ESMO26 on the management of advanced #prostatecancer

[Jaume Capdevila @Ja_Capdevila]

Clinical Complete Response with Dostarlimab Monotherapy in dMMR/MSI-H Locally Advanced Rectal Cancer: First Results from the Global AZUR-1 Trial - Annals of Oncology https://t.co/iai9wqm9YF @VHIO @vallhebron @GrupoTTD

[Vall d’Hebron Institute of Oncology (VHIO) @VHIO]

💗 Recordem les noves dates de la PINK RUN MIR‼️ 🎀
Després del seu ajornament a causa de les condicions meteorològiques, la PINK RUN MIR se celebrarà finalment els dies 7 i 8 de novembre.
📅 Apunta-ho al teu calendari!

👏 Gràcies a totes les persones participants, col·laboradores i organitzadores per la vostra comprensió i suport.

#PINKRUNMIR

[Vall d’Hebron Institute of Oncology (VHIO) @VHIO]

📣 Inscripcions obertes per a la Clinical Winter School! 🔬
El #VHIO i Synapse Barcelona organitzen una formació gratuïta de 2 dies per descobrir com la recerca arriba als pacients.

🎓 Per a estudiants i graduats de biociències.
📅 20-21/11
📍 Auditori Cellex

Inscriu-t’hi!! 👇

[Vall d’Hebron Institute of Oncology (VHIO) @VHIO]

Avui se celebra la 3a edició de la Pink Run Palau, organitzada per l’Associació Sin Teta Hay Paraíso! 💗

Més de 1.050 persones hi han participat i, enguany, la cursa ha recaptat 12.250 €, que es destinaran íntegrament a la recerca del Grup de Càncer de #MamaVHIO.

👏🏻 Gràcies pel vostre compromís i suport!

[Vall d’Hebron Institute of Oncology (VHIO) @VHIO]

20 años de investigación y compromiso con las personas con cáncer. 💙

El 20 de octubre, el #VHIO celebró su 20.º aniversario junto a más de 300 personas, conmemorando dos décadas de avances en investigación traslacional y oncología de precisión. 

👏 ¡Gracias por formar parte de esta historia!
➡️ https://t.co/T5cicnQGBM

#20VHIO

[UroToday.com @urotoday]

Himalayas-1: Rinzimetostat, an Allosteric PRC2 Inhibitor Combined with Darolutamide: A Global Phase 3 Study in #mCRPC Patients Previously Treated With Abiraterone Acetate. Presented by @quimmateo @VHIO, #ESMO26 written coverage by @zklaassen_md > https://t.co/XcjtPxp6wM #ProstateCancer #ClinicalTrials @myESMO

[OncoDaily @oncodaily]

Pablo Cresta Morgado Wins Best Poster Award in Advanced Prostate Cancer at #ESMO2026

@pablo_cresta @VHIO

"Important implications for biomarker-guided use of affordable treatments in resource-limited settings." - Deborah Mukherji (@dmukherji)

https://t.co/Rzlo8grTYt

[Vall d’Hebron Institute of Oncology (VHIO) @VHIO]

20 anys de recerca i compromís amb les persones amb càncer. 💙

El 20 d’octubre, el #VHIO va celebrar el seu 20è aniversari amb més de 300 persones, commemorant dues dècades d’avenços en recerca translacional i oncologia de precisió. 

👏 Gràcies per formar part d’aquesta història!
➡️ https://t.co/omLrhU0Rqx

#20VHIO

[Vall d’Hebron Institute of Oncology (VHIO) @VHIO]

📣 XIII Edición de charlas y talleres para pacientes con #CáncerDeMama‼️
🔹 Taller 1: Salud ósea y de la esfera sexual
🗓️ 19/11 ⏰ 10h 📍Auditorio Edificio Cellex
💬 Dra. Mireia Barceló, Dra. Núria Laia Rodríguez, @alcarazadriana_ y @SandraGarcaLum1

Inscríbete 👉 https://t.co/YOjBQIpucK
#MamaVHIO #VHIODivulga

[Vall d’Hebron Institute of Oncology (VHIO) @VHIO]

💗 ¡Recordamos las nuevas fechas de la PINK RUN MIR‼️ 🎀

Tras su aplazamiento debido a las condiciones meteorológicas, la PINK RUN MIR se celebrará finalmente los días 7 y 8 de noviembre.

📅 ¡Apúntalo en tu calendario!

👏 Gracias a todas las personas participantes, colaboradoras y organizadoras por su comprensión y apoyo.

#PINKRUNMIR

[Vall d’Hebron Institute of Oncology (VHIO) @VHIO]

📣 Ja tenim nova data‼️ La Cursa Corre Contra el Càncer, organitzada per Acsosa Zona Nord, que es va haver d’ajornar a causa del temporal, se celebrarà finalment el 15 de novembre.
Encara sou a temps d’inscriure-us i sumar-vos a aquesta iniciativa solidària en benefici de la recerca en càncer al VHIO. 💙
📅 15/11
Inscripcions obertes! 👉 https://t.co/5ORBRuWYpN

[Vall d’Hebron Institute of Oncology (VHIO) @VHIO]

🔬 The #VHIO team is at #ESMO2026!

Our researchers are in Madrid to present their work, exchange ideas and connect with colleagues from across the oncology community.

Looking forward to a great congress!

[Vall d’Hebron Institute of Oncology (VHIO) @VHIO]

🏆 Congratulations to @pablo_cresta, researcher in #VHIO’s Prostate Cancer Translational Research Group, on winning the Best Poster Award at #ESMO2026!

His poster highlights BioChiP, an academic trial investigating carboplatin in metastatic castration-resistant #prostatecancer.

👏 Well deserved, Pablo!

[Joaquin Mateo @quimmateo]

The #ESMO2026 poster on our academic trial with carboplatin in mCRPC guided by RAD51-IF HRD status is now up in hall 5A. Come by and chat with @pablo_cresta @VHIO work with @Dolmos77 @H12Octubre

[Joaquin Mateo @quimmateo]

8 years after the first release of #ESCAT, it was time to update the framework to reflect evolving trends in drug development. Today we are proud to share ESCAT v2 a standardised ranking of tumour alterations that helps oncologists interpret predictive and resistance biomarkers

[OncoAlert @OncoAlert]

Bienvenidos a Madrid para #ESMO26
🎥 Nueva Educational Capsule | @GuardConsortium
🇪🇸 TALAPRO-3: ¿Un nuevo paso para los PARP inhibitors en prostate cancer hormonosensible?

Dr. Joaquín Mateo (@quimmateo) from @VHIO in Barcelona breaks down the TALAPRO-3 trial, presented at ASCO 2026 and published in the New England Journal of Medicine, alongside @AzadOncology, @neerajaiims and colleagues.

🧬 What did TALAPRO-3 show?

This phase 3 trial evaluated talazoparib + enzalutamide versus placebo + enzalutamide in patients with HRR-altered metastatic hormone-sensitive prostate cancer (mHSPC).

🔹 599 patients enrolled across both treatment arms.

🔹 Radiographic progression-free survival (rPFS) at 3 years: 77% vs. 56% (HR 0.48; 95% CI 0.36–0.65; p<0.001).

🔹 Overall survival (OS): 78% vs. 72% at 3 years in the interim analysis (HR 0.77; 95% CI 0.56–1.04). OS data remain immature.

🔹 Safety matters: Grade ≥3 anemia occurred in 51% of patients receiving talazoparib.

💡 La gran pregunta: ¿Estamos ante un cambio en el papel de los PARP inhibitors, moving them earlier into the hormone-sensitive setting?

Watch Dr. Mateo’s analysis and join the conversation. 👇

🔗 https://t.co/lMcRUuZgZx

#GuardConsortium #TALAPRO3 #ProstateCancer #ASCO2026

GU Oncology colleagues: @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1 @Uro_Oncologist @Ecastromarcos @abraocantoMD @AlvarezMa89031 @OncBrothers @Helena_de_Palma @DrIacovelli @mjuanfi81

OncoALert faculty: @montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @amerseburger @sonpavde @scserendipity1 @Silke_Gillessen @EfstathiouEleni @BraunMDPhD @nataliagandur @brian_rini @AOmlin @realbowtiedoc @AmandaNizamMD @AndreaNecchi @scocmem

[Laura Soucek @LauraSoucek]

So proud to be part of @VHIO's 20-year journey! ❤️

A place where science and clinical practice go hand in hand, with patients at the heart of everything we do. They are the reason why we do what we do!

Here's to the next 20 years! 🎉

https://t.co/CqN3DAOIU5